Abeona Therapeutics (NASDAQ:ABEO) Raised to Hold at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Several other equities analysts also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a report on Monday, November 25th.

Abeona Therapeutics Stock Up 0.3 %

Shares of NASDAQ ABEO opened at $5.88 on Tuesday. The company has a market cap of $255.60 million, a price-to-earnings ratio of -2.19 and a beta of 1.43. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01. The stock has a 50-day moving average price of $5.70 and a two-hundred day moving average price of $5.74.

Institutional Trading of Abeona Therapeutics

Several institutional investors have recently added to or reduced their stakes in ABEO. abrdn plc boosted its position in Abeona Therapeutics by 158.8% during the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after acquiring an additional 200,647 shares during the last quarter. Rosalind Advisors Inc. boosted its position in shares of Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after purchasing an additional 82,000 shares in the last quarter. GSA Capital Partners LLP grew its stake in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 33,831 shares during the period. Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics in the third quarter worth approximately $151,000. Finally, Citigroup Inc. lifted its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the period. 80.56% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.